HTGM - HTGM STOCK NEWS

HTG Molecular Diagnostics (Nasdaq: HTGM) reported preliminary Q1 2021 results, estimating revenue of approximately $1.4 million. The company anticipates a 30% to 40% revenue growth for 2021 compared to 2020 levels, despite challenges from ongoing COVID-19 impacts. Cash and cash equivalents were around $30.8 million as of March 31, 2021. CEO John Lubniewski expressed cautious optimism about recovery, emphasizing a focus on broadening their customer base and developing a new transcriptome panel for launch in Q3 2021. Full results are expected in May 2021.

HTG Molecular Diagnostics reported its financial results for the year ending December 31, 2020, highlighting a revenue decline to $8.5 million from $19.2 million in 2019, attributed primarily to the impacts of COVID-19. Product revenue fell to $7.9 million, linked to reduced clinical trial activities. Net loss from operations increased to $19.6 million, compared to $19.0 million the prior year. Despite challenges, HTG launched an Early Access Program for its new transcriptome panel and reported positive customer diversification trends, with nine new biopharma customers in 2020.

HTG Molecular Diagnostics (Nasdaq: HTGM) announced it will report financial results for the year ending December 31, 2020, after market close on March 25, 2021. The company will also host a conference call at 4:30 PM Eastern Time to discuss these results and provide a corporate update. HTG specializes in NGS-based molecular profiling, utilizing its proprietary HTG EdgeSeq technology to automate complex molecular profiling from various sample types, aiding in precision medicine.

HTG Molecular Diagnostics (Nasdaq: HTGM) has completed feasibility testing for a whole transcriptome panel utilizing HTG EdgeSeq technology. The company released a white paper detailing the prototype's performance in cancer detection compared to RNA sequencing. Key findings include:

• Accuracy in gene expression profiling across multiple cancer types.
• High repeatability with archived samples.
• Proven robustness as an alternative to RNA-Seq.

HTG plans to launch the research-use-only panel in Q3 2021 following optimization and verification.

HTG Molecular Diagnostics announced the resignation of Timothy Johnson as Executive Chairman and Board member. Johnson has been a key figure since 2008, previously serving as CEO. His contributions are praised by the current leadership, highlighting his commitment to advancing precision medicine. Dr. Ann Hanham remains the Lead Independent Director, continuing the company's focus on NGS-based molecular profiling and empowering precision medicine through innovative technology.

HTG Molecular Diagnostics reported preliminary unaudited financial results for 2020, estimating revenue of $8.5 million and total cash, cash equivalents, and short-term marketable securities of $28.7 million as of December 31, 2020. COVID-19 impacted their oncology business, causing delays and suspensions in customer operations. However, the company noted returning strength in the second half of the year and expansion into the immune response market. HTG aims for a successful launch of its new whole transcriptome product in Q3 2021 and will release full 2020 results in March 2021.

HTG Molecular Diagnostics (Nasdaq: HTGM) announced the issuance of Canadian patent number 2877729 for its nuclease protection method to detect nucleotide variants. This technology enhances the detection of variant nucleotides in target nucleic acids and is part of a broader patent family, including a U.S. patent issued in 2017. CEO John Lubniewski emphasized the company's commitment to strengthening its intellectual property portfolio, with over 20 patents related to this technology. The patent is valid until June 2033, bolstering HTG's position in NGS-based molecular profiling.

HTG Molecular Diagnostics (Nasdaq: HTGM) has initiated its Early Access Program for a prototype whole transcriptome panel, allowing select customers to access the technology before its commercial launch. The panel aims to analyze approximately 20,000 mRNA targets, boasting advantages such as small sample size processing without RNA isolation. The company has secured its first collaborator, a top US Cancer Center, indicating strong market interest. HTG expects to enroll additional collaborators from the US and Europe by year-end 2020, advancing towards a commercial launch in mid-2021.

HTG Molecular Diagnostics (Nasdaq: HTGM) has launched an Early Access Program for its new whole transcriptome panel, utilizing HTG EdgeSeq technology. This program allows select customers to test the panel before its commercial release, anticipated in mid-2021. The technology can analyze approximately 20,000 mRNA targets without the need for RNA isolation, which benefits small or low-quality samples. The initiative aims to collect user insights from key opinion leaders in academia and pharmaceuticals to refine the product.